
RAPP Stock Forecast & Price Target
RAPP Analyst Ratings
Bulls say
Rapport Therapeutics is a strong potential investment due to its promising drug pipeline focusing on small-molecule precision medicines for neurological and psychiatric disorders. Their lead asset, RAP-219, has shown strong clinical evidence of efficacy in treating focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. There is a clear commercial opportunity for a well-tolerated, non-antipsychotic agent with even modest efficacy in the bipolar mania market. Additionally, their pipeline has potential for expansion into other indications, such as chronic pain and hearing disorders. With an estimated 30%-40% of patients with multi-drug refractory disease in the US, the potential market for Rapport's therapies is significant.
Bears say
Rapport Therapeutics is a clinical-stage biotechnology company with a negative outlook on its stock due to the high competition in the treatment of bipolar mania and the limited clinical evidence validating RAP-219's novel mechanism of action. While the drug has shown some promise in reducing seizures in epilepsy patients, its efficacy in treating bipolar mania is unproven and the company's Phase 2 trial results are not expected until 4Q26. Furthermore, Rapport's financials have not been publicly disclosed, making it difficult to assess the company's overall financial health.
This aggregate rating is based on analysts' research of Rapport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
RAPP Analyst Forecast & Price Prediction
Start investing in RAPP
Order type
Buy in
Order amount
Est. shares
0 shares